Trial Profile
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via Convection-Enhanced Delivery In Patients With Progressive And/Or Multiple Recurrent Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs BMP 4 (Primary) ; BMP 4 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors StemGen
- 15 Feb 2024 Status changed from active, no longer recruiting to completed.
- 17 Nov 2020 Planned End Date changed from 5 Aug 2019 to 31 Mar 2021.
- 17 Nov 2020 Status changed from recruiting to active, no longer recruiting.